Ask about this productRelated genes to: CYP11B1 Blocking Peptide
- Gene:
- CYP11B1 NIH gene
- Name:
- cytochrome P450 family 11 subfamily B member 1
- Previous symbol:
- CYP11B
- Synonyms:
- P450C11, FHI, CPN1
- Chromosome:
- 8q24.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-10-05
Related products to: CYP11B1 Blocking Peptide
Related articles to: CYP11B1 Blocking Peptide
- Proteinuria is a common manifestation of glomerular disease. Advances in genetic testing have improved recognition of hereditary nephropathies such as LMX1B-associated nephropathy. Coexistence with immune-mediated glomerulonephritis is exceptionally rare. - Source: PubMed
Publication date: 2026/04/16
Sajjad AhsanAmer RidaAlsayed MohammadButt Muhammad DaoudMandayam SreedharSajjad MobeenMasood Attique Ur Rehman - Hypertension remains the world's leading preventable cause of cardiovascular morbidity and mortality. Despite the availability of diverse antihypertensive drug classes, resistant hypertension continues to affect millions globally, leading to a disproportionate risk of stroke, heart failure, kidney disease, and premature death. Aldosterone excess is a central driver of treatment resistance, yet direct pharmacological suppression of aldosterone biosynthesis has long eluded clinical success due to the challenge of selectively targeting aldosterone synthase (CYP11B2) over its near-identical paralog 11β-hydroxylase (CYP11B1). Baxdrostat (CIN-107, RO6836191), an orally bioavailable, highly selective aldosterone synthase inhibitor (ASI), has now demonstrated robust blood pressure reduction in phase 3 clinical trials, marking a potential paradigm shift in the management of resistant hypertension. This Review summarizes the pathophysiology of aldosterone in hypertension, the molecular pharmacology of CYP11B2 inhibition, the discovery and development of Baxdrostat, and its clinical evaluation. We further discuss the broader implications of targeting steroidogenic cytochrome P450 enzymes and highlight future opportunities and challenges as Baxdrostat and related agents enter the cardiovascular pharmacopeia. - Source: PubMed
Publication date: 2026/03/20
Capriello ImmaDömling Alexander - Adrenocortical carcinoma (ACC) is a rare malignancy often associated with disorganized steroid synthesis, leading to variable clinical phenotypes. Etomidate, an imidazole derivative, is a potent inhibitor of adrenal cytochrome P450-dependent enzymes, particularly 11β-hydroxylase (CYP11B1). Subhypnotic doses of etomidate are effective in reducing serum cortisol in patients with severe Cushing syndrome, a common manifestation in ACC. However, the effects of etomidate on other adrenal hormones in ACC remain poorly understood. In this report, we measured 13 steroid hormones before and after etomidate infusion using liquid chromatography-tandem mass spectrometry in a patient with ACC. Etomidate administration led to marked suppression of cortisol and aldosterone, while 11-deoxycorticosterone levels increased substantially. Interestingly, despite the elevated 11-deoxycorticosterone, serum potassium normalized, highlighting a complex interplay among mineralocorticoid precursors and active hormones in maintaining electrolyte balance. - Source: PubMed
Publication date: 2026/04/02
Bhattacharya OliviaSingha ArijitNeogi SubhasisChowdhury Subhankar - Ovulation is a highly regulated inflammatory process that involves the initiation and timely resolution of the inflammation for efficient oocyte maturation. During this process, glucocorticoids accumulate in the pre-ovulatory follicular environment as an anti-inflammatory mediator. However, their temporal regulation, endogenous synthesis, and functional significance on oocyte maturation and subsequent developmental competence remain unclear. - Source: PubMed
Publication date: 2026/04/02
Akter ShahrinaYamanaka TakahiroOkamoto AsakoMiraz Md Faizul HossainShimada Masayuki - Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder shaped by genetic and environmental factors. Phthalates, widely used as plasticizers in consumer products, have gained attention as potential environmental contributors to ASD; however, their pathogenic roles remain insufficiently defined. This study systematically investigated the molecular associations between three common phthalates, diethyl phthalate (DEP), dimethyl phthalate (DMP), and dioctyl phthalate (DOP), and ASD risk using integrated network toxicology and bioinformatics approaches. Intersection analysis of phthalate-associated targets and ASD-related genes revealed shared enrichment in lipid metabolism-related pathways. Protein-protein interaction network analysis identified 10 key targets: FAAH, CYP2C9, CYP24A1, ACHE, CYP11B1, TSPO, PTGS2, MIF, ADORA1, and ALDH3A1. Molecular docking and dynamics simulations indicated stable binding interactions between phthalates and the target. Mendelian randomization analysis further suggested that FAAH and ADORA1 serve as key pathogenic mediators linking phthalate exposure to ASD risk. In vivo experiments demonstrated that C57BL/6 mice exposed to individual or mixed phthalates exhibited ASD-like behaviors, including reduced social interaction, increased repetitive behaviors, and cognitive impairment, with the most pronounced effects observed in the DEP, DMP, and mixed exposure groups. qRT-PCR analysis of hippocampal tissue showed significant downregulation of Faah and upregulation of Adora1 in the DEP group. Collectively, these findings identify FAAH and ADORA1 as central molecular links between phthalate exposure and ASD-related phenotypes from a systems toxicology perspective, providing insight into environmental contributions to neurodevelopment and potential molecular targets for intervention. - Source: PubMed
Publication date: 2026/03/25
Sun YaoLyu LiangZhang XiruiChen ShuangshuangLiu YutongQiao WanyingZhu TikangWang ShutingWang ZuyueZhou DingHai YangFan Lili